Editorial: Targeting the endocannabinoidome in neurodegenerative disorders

Related Articles:

• The radiologist at a Parkinson’s conference October 24, 2022 # # # # In 2015, a woman with dementia was sitting in hospice care, wheelchair-bound and largely non-communicative. As part of a research project, she was given repeated computed tomography (CT) scans of her brain. The effect of this seemingly harmless treatment was rather astonishing, and it has led to more research exploring the effect of low dose ionizing…
• Editorial: Targeting the endocannabinoidome in neurodegenerative disorders January 23, 2023 Front Aging Neurosci. 2023 Jan 4;14:1116635. doi: 10.3389/fnagi.2022.1116635. eCollection 2022.NO ABSTRACTPMID:36688166 | PMC:PMC9846791 | DOI:10.3389/fnagi.2022.1116635
• Editorial: Targeting the endocannabinoidome in neurodegenerative disorders January 23, 2023 Front Aging Neurosci. 2023 Jan 4;14:1116635. doi: 10.3389/fnagi.2022.1116635. eCollection 2022.NO ABSTRACTPMID:36688166 | PMC:PMC9846791 | DOI:10.3389/fnagi.2022.1116635
• Editorial: Targeting the endocannabinoidome in neurodegenerative disorders January 23, 2023 Front Aging Neurosci. 2023 Jan 4;14:1116635. doi: 10.3389/fnagi.2022.1116635. eCollection 2022.NO ABSTRACTPMID:36688166 | PMC:PMC9846791 | DOI:10.3389/fnagi.2022.1116635
• Editorial: Targeting the endocannabinoidome in neurodegenerative disorders January 23, 2023 Front Aging Neurosci. 2023 Jan 4;14:1116635. doi: 10.3389/fnagi.2022.1116635. eCollection 2022.NO ABSTRACTPMID:36688166 | PMC:PMC9846791 | DOI:10.3389/fnagi.2022.1116635
• Parkinson’s and Autoimmunity January 26, 2023 “I am always doing that which I cannot do, in order that I may learn how to do it.” Pablo Picasso “We have more possibilities available in each moment than we realize.” Nhat Hanh Précis: This post exists because I received a note from a reader concerned about using a substance that potentially was an immune enhancer, coupled with the…
• The road ahead: 2022 January 20, 2022 # # # # The first post at the start of each year on the SoPD website tries to provide an overview of where things are in the search for ‘disease modifying’ therapies for Parkinson’s.  It is an exercise in managing expectations as well as discussing what research events are scheduled for the next year so that we can keep…
• The road ahead: 2021 January 25, 2021 # # # # At the start of each year, it is a useful practise to layout what is planned over the next 12 months. The events that are scheduled for the year to come, so that we can keep an eye out for them. Obviously, where 2021 will end actually is unpredictable, but an outline of what is scheduled…
• Monthly Research Review – September 2022 September 30, 2022 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during September 2022. The post is divided into 10 parts based on the type of research: Top 6 pieces of Parkinson’s news Articles of general interest Basic biology…
• A nod to immunomod with fingolimod October 16, 2022 # # # # In general, your immune system does a truly amazing job of keeping you healthy and the dangerous pathogenic world around us at bay. Trillions of cells constantly monitoring for viruses and other illness-causing agents, and ruthlessly disposing of any that they actually find. But sometimes your immune system can get a little carried away with this…
• Potential Anti-Aging and Neuroprotection Strategy for Parkinson’s May 29, 2021 “The years teach much which the days never know.” Ralph Waldo Emerson “Old age is not a disease – it is strength and survivorship, triumph over all kinds of vicissitudes and disappointments, trials and illnesses.” Maggie Kuhn Introduction: This blog post presents a strategy to possibly reduce aging and it may also be neuroprotective in the Parkinson’s brain. The idea…
• The Aging Immune System and Parkinson’s October 10, 2022 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction: Recently, an exciting and in-depth review article about inflammation and the immune system and their dysfunction in the pathway of Parkinson’s was published. The citation for this paper is as follows:…
• The road ahead: 2020 January 5, 2020 Here at the SoPD, we are primarily interested in disease modification for Parkinson’s. While there is a great deal of interesting research exploring the causes of the condition, novel symptomatic therapies, and other aspects of Parkinson’s, my focus is generally on the science seeking to slow, stop or reverse the condition. At the start of each year, it is a…
• Monthly Research Review – July 2021 July 31, 2021 # # # # At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during July 2021. The post is divided into 10 parts based on the type of research: Top 5 pieces of Parkinson’s news Articles of general interest Basic biology…
• 10 Lessons Learned About COVID-19 and Parkinson’s January 8, 2023 “Come grow old with me. The best is yet to be.” William Wordsworth “As long as I am breathing, in my eyes, I am just beginning.” Criss Jami Introduction:  Likely, everyone in the world has said the words “COVID-19 Pandemic” at some point since early 2020. From mid-February 2020 to December 2022, more than 324,000 publications on some aspects of COVID-19…
• Monthly Research Review – November 2020 November 30, 2020   At the end of each month the SoPD writes a post which provides an overview of some of the major pieces of Parkinson’s-related research that were made available during November 2020. The post is divided into seven parts based on the type of research: Basic biology Disease mechanism Clinical research New clinical trials Clinical trial news Conferences/lectures Other news…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…
• The endocannabinoidome mediator N-oleoylglycine is a novel protective agent against 1-methyl-4-phenyl-pyridinium-induced neurotoxicity October 31, 2022 Front Aging Neurosci. 2022 Oct 14;14:926634. doi: 10.3389/fnagi.2022.926634. eCollection 2022.ABSTRACTN-oleoylglycine (OlGly) is a lipid mediator that belongs to the expanded version of the endocannabinoid (eCB) system, the endocannabinoidome (eCBome), which has recently gained increasing attention from the scientific community for its protective effects in a mouse model of mild traumatic brain injury. However, the effects of OlGly on cellular models…